| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 23.85% | Wells Fargo | $290 → $270 | Maintains | Overweight |
| 08/03/2023 | 19.27% | Morgan Stanley | $285 → $260 | Maintains | Overweight |
| 08/02/2023 | 5.96% | Credit Suisse | $247.41 → $231 | Maintains | Outperform |
| 07/31/2023 | 15.14% | Baird | $255 → $251 | Maintains | Outperform |
| 07/28/2023 | 23.85% | Truist Securities | $275 → $270 | Maintains | Buy |
| 06/05/2023 | 32.11% | Credit Suisse | → $288 | Reiterates | Outperform → Outperform |
| 05/16/2023 | 17.89% | Mizuho | $277 → $257 | Maintains | Buy |
| 05/10/2023 | 30.73% | Morgan Stanley | $295 → $285 | Maintains | Overweight |
| 05/01/2023 | 26.15% | Truist Securities | $285 → $275 | Maintains | Buy |
| 03/13/2023 | 32.11% | Credit Suisse | $304 → $288 | Maintains | Outperform |
| 02/21/2023 | 39.45% | Credit Suisse | $305 → $304 | Maintains | Outperform |
| 02/21/2023 | 33.03% | Wells Fargo | $315 → $290 | Maintains | Overweight |
| 02/17/2023 | 30.73% | Truist Securities | $275 → $285 | Maintains | Buy |
| 02/17/2023 | 19.27% | Citigroup | $250 → $260 | Maintains | Neutral |
| 02/17/2023 | 37.61% | Baird | $285 → $300 | Maintains | Outperform |
| 02/17/2023 | 27.06% | Mizuho | $250 → $277 | Maintains | Buy |
| 01/11/2023 | 30.73% | Baird | $270 → $285 | Maintains | Outperform |
| 01/06/2023 | 38.99% | Morgan Stanley | $290 → $303 | Maintains | Overweight |
| 12/12/2022 | 14.68% | Citigroup | → $250 | Downgrades | Buy → Neutral |
| 11/23/2022 | 39.91% | Credit Suisse | $308 → $305 | Maintains | Outperform |
| 11/03/2022 | 14.68% | Mizuho | $296 → $250 | Maintains | Buy |
| 10/31/2022 | 33.03% | Morgan Stanley | $300 → $290 | Maintains | Overweight |
| 10/28/2022 | 19.27% | Truist Securities | $275 → $260 | Maintains | Buy |
| 08/22/2022 | 37.61% | Morgan Stanley | → $300 | Assumes | → Overweight |
| 08/01/2022 | 41.28% | Credit Suisse | $312 → $308 | Maintains | Outperform |
| 07/29/2022 | 35.78% | Mizuho | $323 → $296 | Maintains | Buy |
| 05/25/2022 | 37.61% | Morgan Stanley | $360 → $300 | Maintains | Overweight |
| 05/03/2022 | 21.56% | Deutsche Bank | $294 → $265 | Maintains | Hold |
| 05/02/2022 | 43.12% | Credit Suisse | $344 → $312 | Maintains | Outperform |
| 04/25/2022 | 44.5% | Wells Fargo | $320 → $315 | Maintains | Overweight |
| 02/14/2022 | 65.14% | Morgan Stanley | $380 → $360 | Maintains | Overweight |
| 02/11/2022 | 57.8% | Credit Suisse | $340 → $344 | Maintains | Outperform |
| 01/28/2022 | 34.86% | Deutsche Bank | → $294 | Downgrades | Buy → Hold |
| 12/20/2021 | 62.39% | Mizuho | $332 → $354 | Maintains | Buy |
| 12/17/2021 | 74.31% | Morgan Stanley | $377 → $380 | Maintains | Overweight |
| 12/14/2021 | 55.96% | Wells Fargo | $330 → $340 | Maintains | Overweight |
| 11/01/2021 | 55.05% | Credit Suisse | $336 → $338 | Maintains | Outperform |
| 10/29/2021 | 72.94% | Morgan Stanley | $368 → $377 | Maintains | Overweight |
| 08/31/2021 | 68.81% | Morgan Stanley | $273 → $368 | Maintains | Overweight |
| 08/20/2021 | 54.13% | Credit Suisse | $296 → $336 | Maintains | Outperform |
| 08/19/2021 | 52.29% | Mizuho | $318 → $332 | Maintains | Buy |
| 07/30/2021 | 51.38% | Deutsche Bank | $297 → $330 | Maintains | Buy |
| 07/30/2021 | 45.87% | Mizuho | $310 → $318 | Maintains | Buy |
| 05/20/2021 | 35.32% | Argus Research | $270 → $295 | Maintains | Buy |
| 05/12/2021 | 42.2% | Mizuho | $267 → $310 | Maintains | Buy |
| 05/03/2021 | 42.2% | Jefferies | $300 → $310 | Maintains | Buy |
| 04/14/2021 | 37.61% | Truist Securities | $280 → $300 | Maintains | Buy |
| 02/12/2021 | 22.48% | Mizuho | $242 → $267 | Maintains | Buy |
| 02/12/2021 | 27.52% | Citigroup | $257 → $278 | Maintains | Buy |
| 01/29/2021 | 17.89% | Citigroup | $249 → $257 | Maintains | Buy |
| 01/14/2021 | 11.01% | Mizuho | $234 → $242 | Maintains | Buy |
| 01/11/2021 | — | Argus Research | Upgrades | Hold → Buy | |
| 10/28/2020 | 19.27% | Wells Fargo | $225 → $260 | Maintains | Overweight |
| 07/29/2020 | 10.09% | B of A Securities | $220 → $240 | Maintains | Buy |
| 07/14/2020 | 0.92% | B of A Securities | $194 → $220 | Upgrades | Neutral → Buy |
| 07/13/2020 | -0.46% | Wolfe Research | $202 → $217 | Upgrades | Peer Perform → Outperform |
| 06/08/2020 | 0.46% | Baird | $199 → $219 | Maintains | Outperform |
| 06/02/2020 | -3.67% | Deutsche Bank | → $210 | Reinstates | → Buy |
| 05/21/2020 | 0.92% | SunTrust Robinson Humphrey | $200 → $220 | Maintains | Buy |
| 05/20/2020 | 11.93% | Morgan Stanley | $241 → $244 | Maintains | Overweight |
| 05/15/2020 | -14.68% | Mizuho | $158 → $186 | Upgrades | Neutral → Buy |
| 05/05/2020 | 0% | UBS | $209 → $218 | Maintains | Buy |
| 04/30/2020 | 10.55% | Morgan Stanley | $172 → $241 | Maintains | Overweight |
| 04/30/2020 | -12.84% | B of A Securities | $147 → $190 | Reiterates | → Neutral |
| 04/27/2020 | -1.83% | Citigroup | $204 → $214 | Upgrades | Neutral → Buy |
| 04/23/2020 | -10.55% | Barclays | $188 → $195 | Maintains | Overweight |
| 04/16/2020 | -27.52% | Mizuho | $163 → $158 | Maintains | Neutral |
| 04/13/2020 | -8.26% | SunTrust Robinson Humphrey | $225 → $200 | Maintains | Buy |
| 04/08/2020 | -21.1% | Morgan Stanley | $211 → $172 | Maintains | Overweight |
| 04/02/2020 | -31.65% | JP Morgan | $149 → $149 | Maintains | Overweight |
| 03/30/2020 | -22.02% | Wells Fargo | $215 → $170 | Maintains | Overweight |
| 03/30/2020 | -22.02% | Keybanc | $212 → $170 | Maintains | Overweight |
| 03/26/2020 | -13.76% | Barclays | $212 → $188 | Maintains | Overweight |
| 02/25/2020 | -12.84% | Mizuho | $174 → $190 | Maintains | Neutral |
| 02/18/2020 | -3.21% | Morgan Stanley | $199 → $211 | Maintains | Overweight |
| 02/14/2020 | -6.42% | Citigroup | $179 → $204 | Maintains | Neutral |
| 01/08/2020 | -3.67% | Wells Fargo | → $210 | Initiates Coverage On | → Overweight |
| 10/21/2019 | -8.26% | UBS | $204 → $200 | Maintains | Buy |
| 08/23/2019 | -7.8% | Morgan Stanley | $190 → $201 | Maintains | Overweight |
| 08/08/2019 | -11.93% | Keybanc | $172 → $192 | Maintains | Overweight |
| 07/26/2019 | -12.84% | Morgan Stanley | $175 → $190 | Maintains | Overweight |
| 07/16/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 06/21/2019 | 0.92% | Deutsche Bank | $180 → $220 | Upgrades | Hold → Buy |
| 05/02/2019 | -24.31% | Canaccord Genuity | $155 → $165 | Maintains | Hold |
| 05/01/2019 | -19.27% | Citigroup | $157 → $176 | Maintains | Neutral |
| 05/01/2019 | -10.55% | UBS | $178 → $195 | Maintains | Buy |
| 04/02/2019 | — | Jefferies | Upgrades | Hold → Buy | |
| 03/18/2019 | -20.64% | Barclays | $165 → $173 | Maintains | Overweight |
| 02/27/2019 | -24.77% | Credit Suisse | $160 → $164 | Maintains | Outperform |
| 01/17/2019 | -22.48% | UBS | → $169 | Initiates Coverage On | → Buy |
| 01/03/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 12/06/2018 | -24.31% | Keybanc | $210 → $165 | Maintains | Overweight |
| 12/03/2018 | -24.31% | Barclays | $205 → $165 | Maintains | Overweight |
| 12/03/2018 | -26.61% | Citigroup | $171 → $160 | Maintains | Neutral |
| 12/03/2018 | -28.9% | Canaccord Genuity | $162 → $155 | Maintains | Hold |
| 12/03/2018 | -17.43% | Morgan Stanley | $202 → $180 | Maintains | Overweight |
| 11/30/2018 | -17.43% | Goldman Sachs | $190 → $180 | Downgrades | Conviction Buy → Buy |
| 10/30/2018 | — | Argus Research | Downgrades | Buy → Hold | |
| 10/25/2018 | -12.84% | Baird | $205 → $190 | Maintains | Outperform |
| 10/25/2018 | -21.56% | Citigroup | $184 → $171 | Maintains | Neutral |
| 10/25/2018 | -25.69% | Canaccord Genuity | $195 → $162 | Downgrades | Buy → Hold |
| 09/10/2018 | -7.34% | Morgan Stanley | $192 → $202 | Maintains | Overweight |
| 09/04/2018 | -10.55% | Credit Suisse | $197 → $195 | Maintains | Outperform |
| 08/20/2018 | -12.84% | Deutsche Bank | $195 → $190 | Maintains | Hold |
What is the target price for Laboratory Corp (LH)?
The latest price target for Laboratory Corp (NYSE: LH) was reported by Wells Fargo on August 14, 2023. The analyst firm set a price target for $270.00 expecting LH to rise to within 12 months (a possible 23.85% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Laboratory Corp (LH)?
The latest analyst rating for Laboratory Corp (NYSE: LH) was provided by Wells Fargo, and Laboratory Corp maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Laboratory Corp (LH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Laboratory Corp, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Laboratory Corp was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
Is the Analyst Rating Laboratory Corp (LH) correct?
While ratings are subjective and will change, the latest Laboratory Corp (LH) rating was a maintained with a price target of $290.00 to $270.00. The current price Laboratory Corp (LH) is trading at is $218.00, which is out of the analyst's predicted range.